Mostrando 3 resultados de: 3
Subtipo de publicación
Article(3)
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(1)
Fisiología humana(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Origen
scopus(3)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusErythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study
ArticleAbstract: Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) anPalabras claves:Clinical trial, erythropoietin, human-recombinant erythropoietin, spinocerebellar ataxia type 2Autores:Almaguer Gotay D., Amaro-González D., Aymed-García J., Batista-Nuñez M., Canales-Ochoa N., Carmen Elena Viada, Columbié Ximelis J., Crombet-Ramos T., Estupiñán Rodriguez A., García-García I., García-Rodriguez J.C., Hernández Casaña P., Jiménez-Rodríguez D., Labrada Aguilera P.E., Medrano Montero J., Ortega-Sanchez R., Padrón-Estupiñan M.d.C., Peña Acosta A., Rodríguez-Labrada R., Rodriguez-Obaya T., Santos-Morales O., Silva Ricardo Y., Torres Vega R., Tribin Rivero K., Valenzuela-Silva C.M., Valle Cabrera R., Vazquez-Mojena Y., Velazquez-Perez L.Fuentes:scopusNasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: A randomized, parallel, open-label safety study
ArticleAbstract: Background: Delivery of therapeutic agents as erythropoietin (EPO) into Central Nervous System throuPalabras claves:Healthy volunteers, Hematopoietic activity, neurodegenerative diseases, NeuroEPO, Non-hematopoietic recombinant erythropoietin, safety, strokeAutores:Alfonso-Muñoz E., Amaro-González D., Carmen Elena Viada, Díaz-Machado A., Festary-Casanovas T., García-García I., González-Delgado C.A., Jiménez-Rodríguez D., Pérez-Rodríguez S., Piedra-Sierra P., Pomares-Iturralde Y., Santos-Morales O.Fuentes:scopus